Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines

International Journal of Cancer

Volumn 129, Issue 10, 2011, Pages 2408-2416

  Mimura, Kousaku ^a,b   Kono, Koji ^a   Maruyama, Takanori ^a   Watanabe, Mitsuaki ^a   Izawa, Shinichiro ^a   Shiba, Shugo ^a   Mizukami, Yoshiki ^a   Kawaguchi, Yoshihiko ^a   Inoue, Masayuki ^a   Kono, Tetsuo ^b   Choudhury, Aniruddha ^c   Kiessling, Rolf ^c   Fujii, Hideki ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b Ichikawamisato Municipal Hospital   (Japan)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ADCC; EGFR; esophageal cancer; HER2; Lapatinib

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PROTEIN TYROSINE KINASE; RITUXIMAB; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL GROWTH; CELL SURFACE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TARGET CELL; WESTERN BLOTTING;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; GENES, ERBB-2; HUMANS; NEOPLASMS, SQUAMOUS CELL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79958856696     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25896     Document Type: Article

References (49)

1. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y,. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220: 364-72.
2. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S,. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003; 21: 2697-702. (Pubitemid 46606313)
3. Kato H, Watanabe H, Tachimori Y, Iizuka T,. Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann Thorac Surg 1991; 51: 931-5.
4. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, Takiyama W, Ishida K, Isono K, Makuuchi H, Imamura M, Shinoda M, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001; 31: 419-23. (Pubitemid 33039748)
5. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y,. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16: 5276-87. (Pubitemid 26315047)
6. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37. (Pubitemid 33674041)
7. Citri A, Yarden Y,. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-16. (Pubitemid 44036456)
8. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM,. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437-41. (Pubitemid 46160912)
9. Ghaderi A, Vasei M, Maleck-Hosseini SA, Gharesi-Fard B, Khodami M, Doroudchi M, Modjtahedi H,. The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. Pathol Oncol Res 2002; 8: 252-6. (Pubitemid 36249604)
10. Kimura M, Tsuda H, Morita D, Ichikura T, Ogata S, Aida S, Yoshizumi Y, Maehara T, Mochizuki H, Matsubara O,. A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 2004; 445: 255-62. (Pubitemid 39286893)
11. Hayashi Y, Widjono YW, Ohta K, Hanioka K, Obayashi C, Itoh K, Imai Y, Itoh H,. Expression of EGF, EGF-receptor, p53, v-erb B and ras p21 in colorectal neoplasms by immunostaining paraffin-embedded tissues. Pathol Int 1994; 44: 124-30. (Pubitemid 24072143)
12. Porebska I, Harlozinska A, Bojarowski T,. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000; 21: 105-15. (Pubitemid 30114656)
13. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y,. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004; 17: 895-904. (Pubitemid 38993773)
14. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM,. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002; 196: 17-25.
15. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM,. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003; 200: 290-7. (Pubitemid 36827302)
16. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA,. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003; 41: S29-S42. (Pubitemid 36818993)
17. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F,. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-44. (Pubitemid 35340719)
18. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS,. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7: 1957-62.
19. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12. (Pubitemid 19147683)
20. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, Sanea NA, Al-Dayel F, Al-Mana H, Sheikh SS, Mirlacher M, Tapia C, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 2007; 60: 768-72. (Pubitemid 47056905)
21. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA, Ooi A,. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98: 833-7. (Pubitemid 34286677)
22. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A,. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006; 118: 1173-80. (Pubitemid 43185604)
23. Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, Fujii H,. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007; 97: 494-501. (Pubitemid 47258449)
24. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A, Fujii H,. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005; 92: 1253-60. (Pubitemid 40604400)
25. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E,. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45. (Pubitemid 38944402)
26. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J,. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-31. (Pubitemid 28311914)
27. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L,. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92. (Pubitemid 32222155)
28. Saltz LB, Meropol NJ, Loehrer PJ, Sr, Needle MN, Kopit J, Mayer RJ,. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8. (Pubitemid 41079832)
29. Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A, Fujii H,. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11: 4898-904. (Pubitemid 41557210)
30. Baselga J,. Targeting tyrosine kinases in cancer: the second wave. Science 2006; 312: 1175-8. (Pubitemid 43801135)
31. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652-9. (Pubitemid 39297926)
32. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-9. (Pubitemid 43259947)
33. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM,. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
34. Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG,. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 2006; 66: 404-11. (Pubitemid 43166048)
35. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, Baselga J,. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009; 28: 803-14.
36. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43. (Pubitemid 46021510)
37. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008; 26: 1066-72.
38. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J,. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-30.
39. Mukherjee A, Dhadda AS, Shehata M, Chan S,. Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer. Expert Opin Pharmacother 2007; 8: 2189-204. (Pubitemid 47505592)
40. Ando T, Mimura K, Johansson CC, Hanson MG, Mougiakakos D, Larsson C, Martins da Palma T, Sakurai D, Norell H, Li M, Nishimura MI, Kiessling R,. Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J Immunol 2008; 181: 8382-90.
41. Haigler H, Ash JF, Singer SJ, Cohen S,. Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad Sci USA 1978; 75: 3317-21. (Pubitemid 8389718)
42. Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, Gray JW,. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992; 89: 5321-5.
43. Kim HP, Han SW, Kim SH, Im SA, Oh DY, Bang YJ, Kim TY,. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol Cancer Ther 2008; 7: 607-15.
44. Clynes RA, Towers TL, Presta LG, Ravetch JV,. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6. (Pubitemid 30208162)
45. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B,. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94: 259-67. (Pubitemid 43151545)
46. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10: 5650-5. (Pubitemid 39180938)
47. Mineo JF, Bordron A, Quintin-Roue I, Loisel S, Ster KL, Buhe V, Lagarde N, Berthou C,. Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas. Br J Cancer 2004; 91: 1195-9. (Pubitemid 39336262)
48. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K,. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007; 98: 1275-80. (Pubitemid 46993549)
49. Koninki K, Barok M, Tanner M, Staff S, Pitkanen J, Hemmila P, Ilvesaro J, Isola J,. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 2010; 294: 211-19.